KemPharm (KMPH) announced the appointment of Christopher Posner to serve on the Company’s Board of Directors. Posner is currently the president and CEO of Cara Therapeutics (CARA), a commercial-stage biopharmaceutical company.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KMPH:
- KemPharm Announces Appointment of Christopher Posner as New Independent Director
- KemPharm price target lowered to $19 from $20 at Canaccord
- Hunting for Undervalued, Overlooked Stocks? Analysts Suggest 2 Names to Buy
- KemPharm to Report Third Quarter 2022 Financial Results
- KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
